The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1852-1860

  Campbell, Garland A ^a   Rosner, Mitchell H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT;

ACUTE DISEASE; ADOLESCENT; ADULT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTROLYTE BALANCE; FEMALE; HUMAN; HYPONATREMIA; KIDNEY; KIDNEY DISEASE; MALE; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SYNDROME;

ACUTE DISEASE; ADOLESCENT; ADULT; FEMALE; HALLUCINOGENS; HUMANS; HYPONATREMIA; KIDNEY; KIDNEY DISEASES; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SYNDROME; WATER-ELECTROLYTE BALANCE; YOUNG ADULT;

EID: 58149335160     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02080508     Document Type: Review

References (88)

1. Hall AP, Henry JA: Acute toxic effects of ecstasy (MDMA) and related compounds: Overview of pathophysiology and clinical management. Br J Anaesth 96: 678-685, 2006
2. Siegel RK: MDMA: Non-medical use and intoxication. J Psychoactive Drugs 18: 349-354, 1986
3. Downing J: The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-340, 1986
4. Steele TD, McCann UD, Ricaurte GA: 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): Pharmacology and toxicology in animals and humans. Addiction 89: 539-551, 1994
5. Peroutka SJ: Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) on an undergraduate campus. N Engl J Med 317: 1542-1543, 1987
6. Brown C, Osterloh J: Multiple severe complications from recreational ingestion of MDMA (ecstasy). JAMA 258: 780-781, 1987
7. Gore SM: Fatal uncertainty: Death rate for use of ecstasy or heroin. Lancet 354: 1265-1266, 1999
8. de la Torre R, Farre M, Roset PM, Pizarro N, Abanades S, Segura M, Segura J, Camí J: Human pharmacology of MDMA: Pharmacokinetics, metabolism and disposition. Ther Drug Monit 26: 137-144, 2004
9. Wolff K, Hay A, Sherlock K, Conner M: Contents of ecstasy. Lancet 346: 1100-1111, 1995
10. Cole JC, Sumnall HR: Altered states: The clinical effects of ecstasy. Pharmacol Ther 98: 35-58, 2003
11. Antoniou T, Tseng AL: Interactions between recreation drugs and antiretroviral agents. Ann Pharmacother 36: 1598-1613, 2002
12. Henry JA, Hill IR: Fatal interaction between ritonavir and MDMA. Lancet 352: 1751-1752, 1998
13. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M: Low dose MDMA (ecstasy) induces vasopressin secretion. Lancet 351: 1784, 1998
14. Schifano F: A bitter pill: Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology 173: 242-248, 2004
15. Henry JA: Ecstasy and the dance of death. BMJ 305: 5-6, 1992
16. Henry JA, Jeffreys KJ, Dawling S: Toxicity and deaths from 3,4-methylenedioxymethamphetamine (ecstasy). Lancet 340; 384-387, 1992
17. Regenthal R, Kruger M, Rudolph K, Trauer H, Preiss R: Survival after massive ecstasy (MDMA) ingestion. Intensive Care Med 25: 640-641, 1999
18. Liechti ME, Kunz I, Kupferschmidt H: Acute medical problems due to ecstasy use. Swiss Med Wkly 135: 652-657, 2005
19. Morton J: Ecstasy: Pharmacology and neurotoxicity. Curr Opin Pharmacol 5: 79-86, 2005
20. Dowling GP, McDonagh ET, Bost RO: "Eve" and "ecstasy": A report of five deaths associated with the use of MDEA and MDMA. JAMA 257: 1615-1617, 1987
21. Harries DP, de Silva RN: Ecstasy and intracerebral haemorrhage. Scot Med J 37: 150-152, 1992
22. Rothwell PM, Grant R: Cerebral venous sinus thrombosis induced by ecstasy. J Neurol Neurosurg Psychiatry 56: 1035, 1993
23. Mazur S, Hitchcock T: Spontaneous pneumomediastinum, pneumothorax and ecstasy abuse. Emerg Med 13: 121-123, 2001
24. Andreu V, Mas A, Bruguera M, Salmerón JM, Moreno V, Nogué S, Rodés J: Ecstasy: A common cause of sever acute hepatotoxicity. J Hepatol 29: 394-397, 1998
25. Fahal IB, Sallomi DF, Yaqoob M, Bell GM: Acute renal failure after ecstasy. BMJ 305: 29, 1992
26. Rusyniak DE, Tandy SL, Hekmatyar SK, Mills E, Smith DJ, Bansal N, MacLellan D, Harper ME, Sprague JE: The role of mitochondrial uncoupling in 3,4-methylenedioxymethamphetamine mediated skeletal muscle hyperthermia and rhabdomyolysis. J Pharmacol Exp Ther 313: 629-639, 2005
27. Simpson DL, Rumack BH: Methylenedioxymethamphetamine: Clinical description of overdose, death and review of pharmacology. Arch Intern Med 141: 1507-1509, 1981
28. Barrett PJ, Taylor GT: Ecstasy ingestion: A case report of severe complications. J R Soc Med 86: 233-234, 1993
29. McCann UD, Slate SO, Ricaurte GA: Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Drug Safety 15: 107-115, 1996
30. Shankaran M, Gudelsky GA: Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 61: 361-366, 1999
31. Bronstein DM, Hong J-S: Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J Pharmacol Exp Ther 274: 943-950, 1995
32. Mallick A, Bodenham AR: MDMA induced hyperthermia: A survivor with an initial body temperature of 42.9°C. J Acad Emerg Med 14: 336-368, 1997
33. Hall AP, Lyburn ID, Spears FD, Riley B: An unusual case of Ecstasy poisoning. Intensive Care Med 22: 670-671, 1996
34. Bagley WH, Yang H, Shah KH: Rhabdomyolysis. Intern Emerg Med 3: 210-218, 2007
35. Hall AP: Dantrolene and 'Ecstasy.' Med J Aust 167: 506, 1997
36. Denborough MA, Hopkinson KC: Dantrolene and ecstasy. Med J Aust 166: 165-166, 1997
37. Watson JD, Ferguson C, Hinds CH, Skinner R, Coakley JH: Exertional heat stroke induced by amphetamine analogues: Does dantrolene have a place? Anaesthesia 48: 1057-1060, 1993
38. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene: A review of its pharmacology, therapeutic use and new developments. Anaesthesia 59: 364-373, 2004
39. Kwon C, Zaritsky A, Dharnidharka VR: Transient proximal tubular renal injury following ecstasy ingestion. Pediatr Nephrol 18:820-822, 2003
40. Ninkovic M, Selakovic V, Dukic M Milosavljevic P, Vasiljevic I, Jovanovic M, Malicevic Z: Oxidative stress in the rat kidney due to 3,4-methylenedioxymethamphetamine (ecstasy) toxicity. Nephrology 13: 33-37, 2008
41. Kreth KP, Kovar KA, Schwab M, Zanger UM: Identification of the human cytochrome P450 involved in the oxidative metabolism of "ecstasy"-related designer drugs. Biochem Pharmacol 59: 1563-1571, 2000
42. Ellis AJ, Wendon JA, Portmann B, Williams R: Acute liver damage and ecstasy ingestion. Gut 38: 454-458, 1996
43. Milroy CM, Clark JC, Forrest AR: Pathology of deaths associated with 'ecstasy' and 'eve' misuse. J Clin Pathol 49: 149-153, 1996
44. Bingham C, Beaman M, Nicholls AJ, Anthony PP: Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol Dial Transplant 13: 2654-2655, 1998
45. Hurault de Ligny B, El Haggan W, Comoz F, Lobbedez T, Pujo M, Griveau AM, Bottet P, Bensadoun H, Ryckelynck JP: Early loss of two renal grafts obtained from the same donor: Role of ecstasy? Transplantation 80: 153-156, 2005
46. Citron BP, Hapern M, McCarron M, Lundberg GD, McCormick R, Pincus IJ, Tatter D, Haverback BJ: Necrotizing angiitis associated with drug abuse. N Engl J Med 283: 1003-1011, 1970
47. Bryden A, Rothwell P, O'Reilly P: Urinary retention with misuse of ecstasy. BMJ 310: 504, 1995
48. Woodrow G, Harnden P, Turney J: Acute renal failure due to accelerated hypertension following ingestion of 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol Dial Transplant 10: 399-400,1995
49. Ajealo I, Koenig K, Snoey E: Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med 5: 839-840, 1998
50. Satchell SC, Connaughtoon M: Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br J Hosp Med 9: 495, 1994
51. Holmes SB, Benerjee AK, Alexander WD: Hyponatremia and seizures after ecstasy use. Postgrad Med J 75: 32-33, 1999
52. Maxwell DL, Poilkey MI, Henry JA: Hyponatremia and catatonic stupor after taking "ecstasy." BMJ 307: 1399-1400, 1993
53. Matthai SM, Sills JA, Davidson BC, Alexandrou D: Cerebral edema after ingestion of MDMA ('ecstasy'') and unrestricted intake of water. BMJ 312: 1359, 1996
54. Parr MJ, Low HM, Botterill P: Hyponatremia and death after "ecstasy" ingestion. Med J Aust 166: 136-137, 1997
55. Nuvailis X, Mascians JR, Peracaula R, de Latoree FJ: Hyponatremic coma after ecstasy ingestion. Int Clin Med 23: 480-484, 1997
56. Watson ID, Serlin M, Moncur P, Tames F: Acute hyponatremia. Postgrad Med J 73: 443-444, 1997
57. Holden R, Jackson MA: Near-fatal hyponatremic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). Lancet 347: 1052, 1996
58. Sue YM, Lee YL, Huang JJ: Acute hyponatremia, seizure and rhabdomyolysis after ecstasy use. J Toxicol Clin Toxicol 40: 931-932, 2002
59. Cherney DZ, Davids MR, Halperin MI: Acute hyponatremia and "ecstasy": Insights from a quantitative and integrative analysis. QJM 95: 475-483, 2002
60. O'Connor A, Cluroe A, Couch R, Galler L, Lawrence J, Synek B: Death from hyponatremia-induced cerebral edema associated with MDMA ("ecstasy") use. N Z Med J 112: 255-256, 1999
61. Magee C, Staunton H, Tormey W, Walshe JJ: Hyponatremia, seizures and stupor associated with ecstasy ingestion in a female. Ir Med J 91: 178, 1998
62. Box SA, Prescott LF, Freestone S: Hyponatremia at a rave. Postgrad Med J 73: 53-54, 1997
63. Kessel B: Hyponatremia after ingestion of "ecstasy" [Letter]. BMJ 308: 414, 1994
64. Budisavljevic MN, Stewart L, Sahn SA, Ploth DW: Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("ecstasy") use. Am J Med 326: 89-93, 2003
65. Kalantar-Zadeh K, Nguyen MK, Chang R, Kurtz I: Fatal hyponatremia in a young woman after ecstasy ingestion. Nat Clin Pract Nephrol 2: 283-288, 2006
66. Brvar M, Kozelj G, Osredkar J, Mozina M, Gricar M, Bunc M: Polydipsia as another mechanism of hyponatremia after 'ecstasy' (3,4-methylenedioxymethamphetamine) ingestion. Eur J Emerg Med 11: 302-304, 2004
67. Iovino M, Steardo L: Effects of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur J Pharmacol 113: 99-103, 1985
68. Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA: Hyponatremic states following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") ingestion. QJM 95: 431-437, 2002
69. Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M: Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 965: 399-409, 2002
70. Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA: Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): Is metabolism a contributory factor? J Pharm Pharmacol 53: 1357-1363, 2001
71. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ: The effect of 3,4-methylenedioxyamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135: 649-656, 2002
72. Wolff K, Tsapakis AR, Winstock D, Hartley D, Holt D, Forsling ML, Aitchison KJ: Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing environment. J Psychopharmacol 20: 400-410, 2006
73. White SR, Obraadovic T, Imel KM, Wheaton MJ: The effects of methylenedioxyamphetamine (MDMA, "ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49: 455-479, 1996
74. Bridges TE, Hillhouse EW, Jones MT: The effect of dopamine on neurohypophysial release in vivo and from the rat neural lobe and hypothalamus in vitro. J Physiol 260: 547-666, 1976
75. Schuster VL, Seldin DW: Water clearance. In: Clinical Disturbances of Water Metabolism, edited by Seldin DW, Geibisch G, New York, Raven Press, 1996, pp 51-64
76. Arieff AI, Kozniewska E, Roberts TP, Vexler ZS, Ayus JC, Kucharczyk J: Age, gender and vasopressin affect survival and brain adaptation in rats with metabolic encephalopathy. Am J Physiol 268: R1143-R1152, 1995
77. Ayus JC, Varon J, Arieff AI: Hyponatremia, cerebral edema and non-cardiogenic pulmonary edema in marathon runners. Ann Intern Med 132: 711-714, 2000
78. Gomez-Balaguer M, Pefia H, Morillas C, Hernández A: Syndrome of inappropriate antidiuretic hormone secretion and "designer drugs" (Ecstasy). J Pediatr Endocrinol Metab 13: 437-438, 2000
79. Nuvials X, Masclans JR, Peracaula R, de Latorre FJ: Hyponatraemic coma after ecstasy ingestion [Letter]. Intensive Care Med 23: 480, 1997
80. Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M: Fatal brain oedema after ingestion of ecstasy and benzylpiperazine. Dtsch Med Wschr 126: 809-811, 2001
81. Traub SJ, Hoffman RS, Nelson LS: The "Ecstasy" hangover: Hyponatremia due to 3,4-methylenedioxymethamphetamine. J Urban Health 79: 549-555, 2002
82. Rosenson J, Smolin C, Sporer K, Blanc P, Olson KR: Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med 49: 1641-71, 2007
83. Libiseller K, Pavlic M, Grubweiser P, Rabl W: Case report: Ecstasy - Death risk even outside rave parties. Forensic Sci Int 153: 227-230, 2005
84. Karlovsek MZ, Alibegović A, Balazic J: Our experiences with fatal ecstasy abuse (two case reports). Forensic Sci Int 147[Suppl]: S77-S80, 2005
85. Moyses ZP, Nakandakari FK, Magaldi AJ: Fluoxetine effect on kidney water reabsorption. Nephrol Dial Transplant 23: 1173-1178, 2008
86. Ayus JC, Arieff AI: Postoperative hyponatremia in menstruant females. Ann Intern Med 117: 891-897, 1992
87. Ayus JC, Achinger SG, Arieff AI: Brain cell volume regulation in hyponatremia: Role of gender, age, vasopressin and hypoxia. Am J Physiol Renal Physiology May 7, 2008 [epub ahead of print]
88. Ayus JC: Hyponatremia in marathon runners. N Engl J Med 353: 427-428, 2005